Skip to main content
. 2017 Jun 5;214(6):1643–1653. doi: 10.1084/jem.20160923

Figure 3.

Figure 3.

Hematopoietic but not endothelial deletion of Etv2 impairs HSPC recovery after 5-FU treatment. (A–I) Tie2-Cre;Etv2 CKO, VEC-Cre;Etv2 CKO, Vav-Cre;Etv2 CKO, or littermate control mice were injected with 250 mg/kg 5-FU i.p. After 11 d, BM mononuclear cells were subjected to flow cytometry by using HSPC surface markers to determine absolute cell number (per femur and tibia) of different hematopoietic compartments. (A) Lin cells. (B) KSL (c-Kit+Sca1+Lin) cells. (C) Long-term HSCs (CD34Flt3 KSL). (D) Short-term HSCs (CD34+Flt3 KSL). (E) Multipotent progenitor (CD34+Flt3+ KSL) cells. (F) LK (c-Kit+Sca1Lin) cells. (G) Common myeloid progenitor (CMP; CD34+CD16/32 LK) cells. (H) Granulocyte-macrophage progenitor (GMP; CD34+CD16/32+ LK) cells. (I) Megakaryocyte-erythrocyte progenitor (MEP; CD34CD16/32 LK) cells. n = 4–6 from two independent experiments. *, P < 0.05; **, P < 0.001. Error bars indicate standard error of the mean.